RenovoRx, Inc.
RenovoRx, Inc. (RNXT): 3 pipeline candidates · 1 upcoming catalyst · ~10 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
10.3 months
D/E 0.24 · 0% dilution
Lead: Phase 3
3 candidates
1 upcoming, next in ~75d
7 buys · 0 sells (180d)
A transparent, data-derived signal for RenovoRx, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$39.9M
Cash
$12.4M
Quarterly Burn
$3.7M
Runway
10.3 mo
Revenue
$563K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| cf33 oncolytic virus therapy | Preclinical |
| iag | Phase 3 |
| renovogem | Phase 3 |
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
27
Total value held
$4.3M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 2,894,354 | $2.9M |
| geode capital management, llc | 381,723 | $386K |
| citadel advisors llc | 232,684 | $235K |
| vanguard fiduciary trust co | 157,902 | $159K |
| northwestern mutual wealth management co | 99,460 | $100K |
| nixon peabody trust co | 97,165 | $98K |
| caprock group, llc | 63,940 | $65K |
| northern trust corp | 42,161 | $43K |
| kestra advisory services, llc | 35,520 | $36K |
| xtx topco ltd | 30,511 | $31K |
Showing top 10 of 27 institutional holders of RenovoRx, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in RenovoRx, Inc.'s pipeline?
RenovoRx, Inc. (RNXT) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is RenovoRx, Inc.'s lead drug candidate?
RenovoRx, Inc.'s most advanced tracked candidate is cf33 oncolytic virus therapy (Preclinical) for Difficult-to-access tumors.
What is RenovoRx, Inc.'s next catalyst?
RenovoRx, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: Targeted Intra-arterial Gemcitabine vs. Continuation of IV Gemcitabine Plus Nab-Paclitaxel Following" — expected September 1, 2026.
What is RenovoRx, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, RenovoRx, Inc. has approximately 10.3 months of cash runway.
What is RenovoRx, Inc.'s market capitalization?
RenovoRx, Inc.'s market capitalization is approximately $39.9M.
Get the full picture on RenovoRx, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.